STOCK TITAN
  1. Home
  2. Sec-filings
  3. LQDA
  4. [8-K] Liquidia Corp Reports Material Event

Liquidia (LQDA) set for S&P SmallCap 600 index inclusion on June 22

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Liquidia Corporation filed a report to share that it will be added to the S&P SmallCap 600® Index, effective before the market opens on June 22, 2026. The company highlights this as a milestone reflecting its market capitalization, liquidity, publicly traded float and profitability profile.

Liquidia develops therapies for challenging respiratory and vascular diseases using its PRINT® technology, including YUTREPIA® (treprostinil) inhalation powder, the investigational L606 formulation and a marketed generic Treprostinil Injection. The company notes that forward-looking statements about visibility, strategy and long-term value are subject to risks described in its SEC filings.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Index inclusion effective date June 22, 2026 Date Liquidia will be added to S&P SmallCap 600
Press release date June 8, 2026 Date Liquidia announced S&P SmallCap 600 inclusion
Index size 600 companies Number of U.S. small-cap companies in S&P SmallCap 600
S&P SmallCap 600 financial
"it will be added to the S&P SmallCap 600® Index, effective prior"
A stock market index made up of 600 small-cap U.S. companies chosen to represent the performance of smaller publicly traded firms. It matters to investors because it acts like a temperature gauge for the small-company segment of the market, serving as a benchmark for fund managers, a basis for index funds and ETFs, and a way to compare returns and risk when building a diversified portfolio.
PRINT® technology technical
"through precise, innovative therapies and applications of its proprietary PRINT® technology."
YUTREPIA® (treprostinil) inhalation powder medical
"PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder"
forward-looking statements regulatory
"This press release may include forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
pulmonary arterial hypertension (PAH) medical
"for the treatment of pulmonary arterial hypertension (PAH) and pulmonary"
Pulmonary arterial hypertension (PAH) is a progressive condition where the blood vessels that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure and extra strain on the heart. For investors it matters because PAH creates long-term demand for medical care and specialized drugs; advances, trial results, or regulatory approvals can meaningfully change treatment costs, hospital use, and the commercial prospects for therapies — like fixing a clogged hose to relieve an overworked pump.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001819576 0001819576 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 8, 2026

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (919) 328-4400 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On June 8, 2026, Liquidia Corporation, a Delaware corporation, issued a press release announcing that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated June 8, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

June 8, 2026 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer and Chief Operating Officer

 

 

 

Exhibit 99.1

 

Liquidia Corporation Announces Inclusion
in the S&P SmallCap 600® Index

 

MORRISVILLE, N.C. (June 8, 2026) — Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.

 

Introduced in 1994, the S&P SmallCap 600 is a widely followed benchmark of 600 U.S. small-cap companies selected by S&P Dow Jones Indices based on market capitalization, liquidity, shares available for public trading, and profitability criteria.

 

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Inclusion in the S&P SmallCap 600 is a meaningful marker of how far Liquidia has come, and it is a credit to the entire team. It reflects the discipline and execution behind our progress and the foundation we have built through our commitment to patients, innovation and operational excellence. We are focused on the opportunities ahead as we continue our work to revolutionize care for patients with challenging respiratory and vascular diseases.”

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding the timing and anticipated impact of the Company’s inclusion in the S&P SmallCap 600 Index, potential enhanced visibility within the investment community, as well as the Company’s strategy, operating priorities and future performance, including statements regarding market capitalization, liquidity, financial viability and long-term value creation, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “will,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investors:

Jason Adair

Chief Business Officer

919.328.4350

 

Media Contact:

media@liquidia.com

 

###

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Liquidia (LQDA) announce in this 8-K filing?

Liquidia announced it will be added to the S&P SmallCap 600® Index, effective before trading opens on June 22, 2026. The company furnished a press release as an exhibit and reiterated its focus on therapies for respiratory and vascular diseases using its PRINT® technology platform.

When will Liquidia (LQDA) join the S&P SmallCap 600 Index?

Liquidia is scheduled to be added to the S&P SmallCap 600® Index before the opening of trading on June 22, 2026. The inclusion was announced in a June 8, 2026 press release furnished as an exhibit to the company’s current report on Form 8-K.

How does Liquidia (LQDA) describe the significance of its S&P SmallCap 600 inclusion?

CEO Dr. Roger Jeffs called the S&P SmallCap 600 inclusion a meaningful marker of how far Liquidia has come. He linked it to the team’s discipline, execution, and commitment to patients, innovation and operational excellence across its respiratory and vascular disease programs.

What therapies and products does Liquidia (LQDA) highlight in this filing?

Liquidia highlights YUTREPIA® (treprostinil) inhalation powder for PAH and PH-ILD, its investigational L606 extended-release treprostinil formulation for nebulization, and its marketed generic Treprostinil Injection for PAH. All leverage the company’s PRINT® technology designed for precise, innovative pulmonary and vascular drug delivery.

Does Liquidia (LQDA) include forward-looking statements in this disclosure?

Yes. The company states that comments on the timing and impact of index inclusion, potential enhanced investment community visibility, strategy, operating priorities and long-term value are forward-looking. It cautions that actual results may differ due to risks described in its SEC filings and competitive industry dynamics.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents